Trial Profile
The Role of Phosphodiesterase Inhibitors in Incretin Secretion
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 May 2022
Price :
$35
*
At a glance
- Drugs Roflumilast (Primary) ; Sitagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- 20 Sep 2016 Status changed from recruiting to completed.
- 21 Feb 2015 New trial record